Copyright
©2014 Baishideng Publishing Group Inc.
World J Hepatol. May 27, 2014; 6(5): 326-339
Published online May 27, 2014. doi: 10.4254/wjh.v6.i5.326
Published online May 27, 2014. doi: 10.4254/wjh.v6.i5.326
Table 12 SVR rate in genotype 1 hepatitis C virus patients n (%)
| GS-9256 + tegobuvir(n = 15) | GS-9256 + tegobuvir + ribavirin by weight (n = 13) | GS-9256 + tegobuvir + ribavirin by weight + PEG-IFNα(n = 14) | |
| Week 4, RVR | 1/15 (7) | 6/13 (46) | 10/14 (71) |
| Week 12, EVR | 3/15 (20) | 8/13 (62) | 14/14 (100) |
| Week 24, SVR | 10/15 (67) | 13/13 (100) | 13/14 (94) |
- Citation: Bakulin I, Pasechnikov V, Varlamicheva A, Sannikova I. NS3 protease inhibitors for treatment of chronic hepatitis C: Efficacy and safety. World J Hepatol 2014; 6(5): 326-339
- URL: https://www.wjgnet.com/1948-5182/full/v6/i5/326.htm
- DOI: https://dx.doi.org/10.4254/wjh.v6.i5.326